Damon-Perrière Nathalie, Tison François, Meissner Wassilios G
Service de neurologie, Centre de référence national maladie rare atrophie multisystématisée, CHU de Bordeaux, Hôpital du Haut-Lévêque, Pessac.
Psychol Neuropsychiatr Vieil. 2010 Sep;8(3):179-91. doi: 10.1684/pnv.2010.0212.
Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder of unknown etiology. It is the most frequent disorder among atypical parkinsonism with an estimated prevalence of 2 to 5 per 100 000 inhabitants. The clinical symptoms are rapidly progressing with a mean survival ranging between 6 to 9 years. The diagnosis is based on consensus criteria that have been revised in 2008. The diagnostic criteria allow defining "possible", "probable" and "definite" MSA. The latter requires post mortem confirmation of striatonigral and olivopontocerebellar degeneration with alpha-synuclein containing glial cytoplasmic inclusions. The diagnosis of "possible" and "probable" MSA is based on the variable presence and severity of parkinsonism, cerebellar dysfunction, autonomic failure and pyramidal signs. According to the revised criteria, atrophy of putamen, pons, middle cerebellar peduncle (MCP) or cerebellum on brain magnetic resonance imaging are considered to be additional features for the diagnosis of "possible" MSA. T2-weighted brain imaging may further reveal a putaminal hypointensity, a hyperintense lateral putaminal rim, the so called "hot cross bun sign" and MCP hyperintensities. Cardiovascular examination, urodynamic testing and anal sphincter electromyography may be helpful for the diagnosis of autonomic failure. Some patients may respond to levodopa, but usually to a lesser extent than those suffering from Parkinson's disease, and high doses are already required in early disease stages. No specific therapy is available for cerebellar dysfunction, while effective treatments exist for urinary and cardiovascular autonomic failure. Physical therapy may help to improve the difficulties of gait and stance, and to prevent their complications. In later disease stages, speech therapy becomes necessary for the treatment of dysarthria and dysphagia. Percutaneous gastrostomy is sometimes necessary in patients with severe dysphagia. Beyond these strategies, psychological support, social care and occupational therapy to adapt the environment to the patient's disability are prerequisites for improving the quality of life in MSA patients.
多系统萎缩(MSA)是一种病因不明的散发性神经退行性疾病。它是非典型帕金森综合征中最常见的疾病,估计每10万居民中患病率为2至5例。临床症状进展迅速,平均生存期为6至9年。诊断基于2008年修订的共识标准。诊断标准可用于定义“可能”、“很可能”和“确诊”的MSA。后者需要在死后通过含有α-突触核蛋白的胶质细胞胞质内含物来证实纹状体黑质变性和橄榄脑桥小脑变性。“可能”和“很可能”MSA的诊断基于帕金森综合征、小脑功能障碍、自主神经功能衰竭和锥体束征的不同程度的存在和严重程度。根据修订后的标准,脑磁共振成像显示壳核、脑桥、小脑中脚(MCP)或小脑萎缩被认为是诊断“可能”MSA的附加特征。T2加权脑成像可能进一步显示壳核低信号、壳核外侧高信号边缘,即所谓的“热交叉面包征”以及MCP高信号。心血管检查、尿动力学检测和肛门括约肌肌电图可能有助于自主神经功能衰竭的诊断。一些患者可能对左旋多巴有反应,但通常程度低于帕金森病患者,且在疾病早期阶段就需要高剂量使用。目前尚无针对小脑功能障碍的特异性治疗方法,而对于泌尿和心血管自主神经功能衰竭则有有效的治疗方法。物理治疗可能有助于改善步态和姿势困难,并预防其并发症。在疾病后期,言语治疗对于构音障碍和吞咽困难的治疗变得必要。严重吞咽困难的患者有时需要进行经皮胃造瘘术。除了这些策略外,心理支持、社会关怀和职业治疗以根据患者的残疾情况调整环境是提高MSA患者生活质量的先决条件。